FDA Rallies Around Pradaxa with New Study, Still No Antidote
By EsqSocial Corporation 20/05/14
A review by the FDA finds no additional risk of myocardial infarcation (MI) or a heart attack when Pradaxa (dabigatran) is compared to Coumadin (warfarin). An MI occurs when blood suddenly stops flowing to parts of the heart injuring the heart...
By: Searcy Denney Scarola Barnhart & Shipley